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REVIEW
Abstract: Mucositis pain is a major clinical problem associated with cancer treatment.
Mucosal tissue injury is a dose-limiting side effect and also limits nutritional intake and oral
function, resulting in weight loss and nutritional deficits for many patients. The
pathophysiology of mucositis is thought to be a complex array of cytokine-mediated events,
which begins with mucosal atrophy and eventually leads to the painful ulceration of the
mucosa. This article reviews current research related to pain management for mucositis.
Effective treatment for mucositis pain must be targeted at the various factors involved in the
pain experience. Although a number of interventions aimed to prevent and treat mucositis
have been studied, there is little evidence to recommend any one treatment modality. While
current strategies for pain management rely on general treatment for acute pain, research
developments are aimed at targeting the specific receptors and enzymes involved in mucositis.
As these breakthroughs become available clinically, thorough assessment and timely directed
interventions must be implemented in order to limit patient distress from mucositis. This
article presents an assessment tool specific to mucositis pain, including physical, functional,
and pain parameters.
Keywords: mucositis, pain management, stomatitis, assessment
Introduction
Chemotherapy agents continue to be the mainstay of cancer treatment, but side effects
on highly proliferative tissues remain significant. Radiation therapy also affects rapidly
dividing cells, putting patients receiving combined treatment modalities at increased
risk for treatment-related toxicity. Among these is mucositis, a general term that
describes the inflammatory response of mucosal epithelial cells to the cytotoxic effects
of chemotherapy. Mucositis can affect all mucous membrane-covered surfaces from
the mouth to the rectum (Camp-Sorrell 2000). Despite intestinal damage, much of
the research and assessment tools continue to focus on oral sequela.
Mucositis can affect up to 100% of bone marrow transplant (BMT) patients, and
is the most frequent serious side effect of therapy in the first 100 days after transplant
(Epstein and Schubert 2004) and is the most common condition requiring system
analgesics during cancer therapy (Epstein and Schubert 1999). Oral mucositis also
affects up to 80% of patients receiving radiation for head and neck malignancies
(Rubenstein et al 2004) and approximately 40% of patients undergoing chemotherapy
(Wojtaszek 2000). While the incidence and severity of mucositis may vary greatly
among patient populations, it significantly reduces quality of life and patients’
experience of treatment. Unresolved or untreated mucositis can lead to infections,
impaired nutritional status, and other complications that can increase morbidity, and
impact patient outcomes. Mucositis is a dose-limiting toxicity for both chemotherapy
and radiation therapy, and therefore can directly impact survival (Avritsher et al
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2004). The need for opioid analgesics can cause extended
hospital stays, which may in turn create further
complications and increase costs.
The purpose of this paper is to explore pain mechanisms
and treatments for pain associated with mucositis to better
manage this difficult toxicity. A mucositis-specific pain
assessment tool is also presented, with potential clinical
interventions tailored to assessment findings.
Mucositis and oral pain
Pain, oral dysfunction, and gastrointestinal distress are
commonly experienced by patients with mucositis,
independent of the grade or severity. The rapid rate of mitosis
in mucosal tissue makes it highly prone to injury from both
chemotherapy and radiation. Mucositis can affect nutritional
status, speech, comfort, and treatment compliance. The pain
from oral mucositis has been reported as the most distressing
symptom by patients receiving treatment for head and neck
cancer, and chemotherapy (Rose-Ped et al 2002). Pain must
be appropriately managed to best ensure positive outcomes
for patients with mucositis.
Cancer treatment-induced mucositis causes acute pain,
which is the result of sloughing of the epithelium,
inflammation of the mucosa, and ulceration (Camp-Sorrell
2000). Tissue injury activates nociceptive receptors creating
pain that resolves with the underlying tissue damage. The
mechanism of pain perception and response are due to four
distinct neural processes. Understanding the neurobiologic
mechanisms of pain will allow for the development of
therapeutic agents that target specific receptors,
neurotransmitters and sites, which will improve management
of mucositis pain.
BMT patients frequently describe acute oral pain as sore,
burning, dull, and aching (McGuire et al 1998). In their
pilot study, McGuire and colleagues (1998) use a framework
based on the gate control theory of pain, introduced by
Melzack and Wall (1965), which confirms the
multidimensional nature of pain. Five dimensions are
generally recognized, including physiologic, sensory,
affective, cognitive, and behavioral dimensions. McGuire
and colleagues (1998) added the sociocultural dimension
as a sixth dimension of pain when evidence of the
relationship between pain and its interference with daily
activities, social relationships, and role performance was
found. Because these pain dimensions exist for patients with
mucositis, a better understanding of them can aid us in
developing effective treatments.
Verbal descriptions of pain in the study by McGuire and
colleagues (1998) most commonly included tender, sore,
and irritating, with each word being mentioned almost 40
times over the study period. Patients’ reports of overall pain
relief during the study period suggested that their pain was
only partially relieved. This finding suggests the need for
careful and frequent nursing assessment and management.
The authors conclude that multiple interventional
approaches are needed to decrease the distress caused by
acute oral pain and mucositis (McGuire et al 1998). A
mucositis-specific pain protocol should address all elements
of pain including tissue damage, sensitization of pain
receptors, and elaboration of inflammatory and pain
mediators (Epstein and Schubert 1999). These elements
correspond to knowledge of the pathophysiology of mucosal
tissue injury.
Pathophysiology
Recent developments in mucositis research indicate
multiple factors which contribute to mucosal injury. The
cytotoxic drugs most frequently associated with mucositis
include bleomycin, cytarabine, doxorubicin, etoposide,
5-fluorouracil, ifosfamide, mercaptopurine, methotrexate,
paclitaxel, vinblastine, vincristine, and vinorelbine
(Dodd, Dibble, et al 2000; Raber-Durlacher et al 2000;
Brown and Wingard 2004). High dose methotrexate,
etoposide, and melphalan, as well as hyperfractionated
radiation are implicated in the most severe forms of
mucositis (Kwong 2004). Although these agents are all
known to cause mucositis, there is still a great deal of
patient variation in the severity of mucositis, even among
patients receiving identical treatment regimens. Although
it is not clear to what extent patient factors correlate with
mucositis prevalence, several are identified in the
literature, including age, nutritional status, and oral
health. Other risk factors include: radiation treatment
history; salivary gland dysfunction; physical, chemical
and thermal mucosal injury; microbial flora; and graft-
versus host disease (Sonis 1998).
A number of biologic products impact the severity and
extent of mucositis, including epidermal growth factor,
tumor necrosis factor-α, and cytokines such as granulocyte-
macrophage colony simulating factor and interleukin-1
(Epstein and Schubert 1999). Radiation and chemotherapy
also alter normal oral microbial flora, and salivary quantity
and composition (Turhal et al 2000). The combination of
treatment-related effects and cytokines leads to mucosalTherapeutics and Clinical Risk Management 2006:2(3) 253
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atrophy, collagen breakdown, and eventual ulceration of the
mucosa.
Sonis (2004) recently revised and expanded the phases
of biologic development of mucositis. Whereas previously
the clinical course of mucositis appeared to follow the same
patter of suppression and recovery of white blood cells
(Sonis 1998), recent work suggests that a complex array of
biologic events generates mucosal tissue injury and healing.
The events of the five phases are summarized in Table 1.
These phases are interdependent and mediated by the action
of cytokines, chemotherapy, oral bacterial flora, and bone
marrow status. In the initial phase, free radicals break DNA
strands and cause a small proportion of cells to die quickly.
Tissue injury from activation of numerous biologic control
mechanisms characterizes the second and third phases.
Transcription factors such as nuclear factor-κ B are activated
and upregulate genes that control synthesis of cytokines.
Both chemotherapy and radiation treatment activate
enzymes that increase the rate of apoptosis, which further
adds to the chemical insults to the mucosa. Ulceration
penetrating through the epithelium into the submucosa
occurs in the fourth phase and creates the loss of function
and pain typical of mucositis. Also in this phase, cell-wall
products from colonizing bacteria stimulate macrophages
to release additional cytokines. The fifth and final phase of
mucositis is related to healing that occurs by migration,
proliferation, and differentiation of epithelial cells (Sonis
2004). The complexity of this process contributes to the
variety of patient experiences and the difficulties clinicians
face in preventing and managing mucositis. As our
understanding of these biologic events improves, more
targeted therapies and interventions may be possible.
Clinical manifestations
The physical symptoms of mucositis begin 5 to 10 days
after chemotherapy. According to Epstein and Schubert
(1999), damage is often bilateral and involves
nonkeratinized sites, including the buccal and labial mucosa,
tongue, soft palate, and floor of the mouth. The gingival
and hard palate are rarely involved (Camp-Sorrell 2000).
Clinical manifestations progress from erythema, cracking,
and inflammation, to pain, bleeding and ulceration. Pain
may be present with any of these symptoms. The clinical
presentation usually begins with mild focal changes, which
can progress to marked tissue changes, bleeding, and pain
(Raber-Durlacher et al 2000).
Epstein and Schubert note that during cancer treatment,
oral mucositis is the most common condition that requires
systemic analgesics. Intense mucositis pain can interfere
with speaking, swallowing, and eating. As previously noted,
additional sequele include bacterial and fungal infections,
xerostomia, weight loss, dehydration, and nutritional
deficiencies. Although oral complications are most
frequently addressed in the literature, mucositis can occur
along the entire gastrointestinal (GI) tract. According to
McGuire (2002), there is almost no literature on pain
associated with GI mucositis. Further research is necessary
to establish the incidence, duration, and characteristics of
pain related to different treatment regimens that cause
mucosal tissue injury.
Assessment
To appropriately manage oral complications, specific,
careful oral assessment is crucial for all patients, with special
attention for patients at high risk of developing mucositis.
Assessment of patients’ oral health, physical, and nutritional
status are important to identify risk factors and appropriate
interventions. All of the assessment tools in the literature
focus on oral assessment. There is very little mention, if at
all, of symptoms in the esophagus or the gastrointestinal
tract.
A number of assessment tools are available, many which
have been developed for research purposes. These include
the World Health Organization (WHO) grading scale, the
oral assessment guide (OAG), the cancer and leukemia
group B (CALGB) assessment guide and others listed in
Table 1 Biological stages of mucositis
Initiation Message generation Signaling and amplification Ulceration Healing
Direct irreversible and Transcription factors such as Apoptosis and tissue injury Epithelial integrity Intact wound
reversible damage to DNA NF-κ B, upregulate a number destroyed. surface forms,
of genes in the epithelium, Bacteremia and continued epithelial
causing increased production sepsis possible. proliferation.
of messaging and effector
proteins.
Abbreviations: DNA, deoxyribonucleic acid; NF, nuclear factor.Therapeutics and Clinical Risk Management 2006:2(3) 254
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Table 2. These numerous assessment tools have a variety of
strengths and weaknesses. The recently published clinical
practice guideline for mucositis (Rubenstein et al 2004)
notes that mucositis research does not use consistent scoring
systems or consistent endpoints, which impedes progress
aimed at prevention and treatment. Ideally an universally
accepted assessment tool would be objective, demonstrate
content validity and inter-user reliability. It also should be
simple enough as to not be time-consuming for nurses or
overwhelming to patients. The lack of consensus regarding
accurate mucositis assessment is confounded when
incorporating a thorough pain assessment. The current
mucositis assessment tools do not incorporate pain
assessment and this addition would be challenging. The
range of assessment parameters (physiological, sensory,
affective, cognitive, behavioral, and sociocultural) could
become sufficiently cumbersome as to not be effective in
clinical practice. For this reason, pain assessment tools
widely used in clinical practice tend to focus on one
dimension of pain. Visual analogue scales (VAS) or verbal
descriptor scales (VDS) are written measures of pain
intensity that are commonly used (Yeager 2000). The
numeric (0 to 10) verbal version of the VDS is also widely
used and has been demonstrated to be reliable and valid.
Yeager (2000) explains that considerations when choosing
an appropriate pain assessment tool should include the
relevant dimensions of pain, the purpose of the assessment
(baseline vs ongoing), current pain interventions, and time
and feasibility.
There is little information in the literature addressing
assessment of mucositis-specific pain. The mucositis
grading systems are partially based on the presence of pain,
but do not address how this pain is assessed. These grading
systems do not address severity, duration, or location of pain.
An assessment tool developed specifically for mucositis pain
which includes dimensions of pain, functional ability, and
effectiveness of interventions is presented in Table 3. This
tool has not yet been validated. However, it incorporates
aspects of many validated tools. It allows documentation of
pain locations and intensities on a 0–10 scale, and patients’
ability to swallow, eat, and talk are scored as able, with
difficulty, or unable. An area is provided for the nurse to
document visual assessment and interventions. The patient’s
response to interventions is rated on a 0–4 scale with 0
indicating a total response and 4 indicating significant
worsening of symptoms. To use the tool effectively, nurses
should implement it early in treatment. Thorough oral
assessment should occur daily in the inpatient setting and
at each outpatient appointment, with reassessment occurring
during subsequent visits. This tool allows nurses in clinical
practice to provide tailored interventions and assess the
response to those interventions in a standardized way that
can not occur with other available assessment tools.
Management
As with mucositis assessment, the wide variety of modalities
aimed at prevention and treatment of mucosal injury creates
a great deal of confusion for patients and clinicians alike.
The section will summarize the most recent research
findings, focusing on agents that have been studied using
pain and functionality as endpoints.
Basic oral care
The purpose of basic oral care is to maintain the patient’s
baseline oral health and reduce the impact of cancer therapy
on the oral mucosa. Good oral hygiene practices are thought
to reduce pain, bleeding, infection,and dental complications
(Rubenstein et al 2004). There is not a consensus on what
constitutes a standard for oral care. The clinical practice
guideline for mucositis (Rubenstein et al 2004) provides a
recommendation level B that oral care protocols be
implemented. Multiple studies (Graham et al 1993; Dibble
et al 1996; Larson et al 1998; Yeager et al 2000) demonstrate
Table 2 Mouth assessment tools
Name of tool Scale Anatomic Functional Comments
measures measures
WHO Criteria 0–4 Yes Yes
OAG 8–24 Yes Yes Assesses voice and talking
MacDibbs mouth assessment 0–21 Yes Yes Includes fungal and viral cultures
Spijkervet scoring system 0–4 Yes No
OMI Yes No
CALGB assessment guide 0–4 Yes Yes
Lorentz mucositis index 0–36 Yes No Schulz-Kindermann et al 2002
Abbreviations: CALGB, cancer and leukemia group B; OAG, oral assessment guide; OMI, oral mucositis index; WHO, World Health Organisation.Therapeutics and Clinical Risk Management 2006:2(3) 255
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the use of systematic protocols to improve patient outcomes.
Components of an oral care protocol are outlined in Table
4.
Topical agents
Topical anesthetics such as viscous lidocaine are frequently
combined with other agents to make mouthwashes. Other
commonly used ingredients include dyphenhydramine, milk
of magnesia, and chlorhexidine. To date, there is no
significant evidence that these mouthwashes are effective
(Rubenstein et al 2004). Dodd, Dibble, and colleagues
(2000) performed a randomized clinical trial with 142
patients to evaluate the effectiveness of three different
mouthwashes for chemotherapy-induced mucositis, and
found evidence to support only routine oral hygiene, and
the use of the inexpensive salt and soda mouthwash.
Turhal et al (2000) tested a mouthwash consisting of
125 ml (100 mg) diphenhydramine, one ampule of 2%
(100 mg) lidocaine, and two ampules of 8.4% sodium
bicarbonate to 1000 ml of sterile saline. This combination
is easy to prepare and administer, and the ingredients are
readily available at low cost. The subjects in the study (n=31)
were told to swish 20 mL of the solution inside their mouths
and spit it out every 2 to 3 hours as needed. Scores were
recorded for mucositis, bleeding, white blood cells,
infection, taste, and metabolism according to the CALGB
expanded common toxicity criteria. Findings support use
of this mouthwash for relief of pain, however, the study
sample is small and lacks a control group. The authors could
only conclude that trials with other commercially available
mouthwashes and new therapies are needed to determine
the superiority of any particular regimen.
Other topical agents that have been studied related to
pain management include sucralfate and dibucaine film.
Sucralfate is an aluminum salt of sucrose orasulfate used to
treat duodenal and gastric ulcer diseases. In addition to
forming a protective physical barrier, sucralfate induces
prostaglandin and mucus production, increases mucosal
blood flow, and increases growth factor binding (Castagna
et al 2001). Although it has been studied in ten randomized
clinical studies, results are conflicting. Cengiz et al (1999)
and Ertiz et al (2000) report reduction in mouth pain during
feeding and a decrease in use of topical anesthetic or
systemic analgesia respectively. Castagna et al (2001)
reported a significant decrease in diarrhea in BMT patients
treated with sucralfate and a higher caloric intake in this
group. The current guideline (Rubenstein et al 2004)
recommends that oral sucralfate not be used because of lack
of evidence and potential for GI side effects. There is a level
III grade B recommendation for sucralfate enemas to manage
chronic radiation-induced proctitis with rectal bleeding,
however. Further evaluation of the effectiveness of sucralfate
is needed to determine its role in pain management and
potential mucositis prophylaxis.
Phase III trials with benzydamine topical rinse show
some promise both for pain relief and radiation-induced
mucositis prevention. The current clinical practice guideline
(Rubenstein et al 2004) includes a level I grade A
recommendation for its use in patients receiving moderate-
dose radiation for head and neck cancer. Randomized trials
Table 3 Harris mucositis-related pain assessment tool
Time Pain Swallow Eat Talk Visual assessment Intervention Response to intervention
Location Intensity
Location Intensity Swallow Eat Talk Visual assessment Intervention Response to intervention
Lips, 0–10 A–able A–able A–able Color, presence of ulcers, Early–oral care,  Patient rating based on decrease in
tongue, W–with W–with W–with red areas, white areas, saline or pain intensity, 
mucosa, difficulty difficulty difficulty dryness bicarbonate rinses 0–total response
gingiva, U–unable U–unable U–unable Middle–local 1–some improvement in symptoms
esophagus, treatment such 2–no difference
stomach, as sucralfate or 3–some worsening of symptoms
gut, anus benzydamine if 4–significant worsening of symptoms
available
Late–systemic
analgesicsTherapeutics and Clinical Risk Management 2006:2(3) 256
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indicate pain relief and reduced opioid use (Epstein and
Schubert 2004). Other topical agents that may demonstrate
a role in pain management include doxepin, a trycyclic
antidepressant, topical morphine sulfate, and topical
capsaicin. Further understanding of the mechanism of
substance P and inflammation will be necessary to determine
the place these agents may have alongside established
systemic analgesics.
Growth factors
Current understanding of the biologic process of mucosal
injury reveals the potential role of a variety of growth factors
for both prevention and treatment. A summary of growth
factor mouthwash trials is included in Table 5. The results
of studies with agents such as tetrachlorodecaoxide,
granulocyte-colony stimulating factor (GCSF), granulocyte-
macrophage colony-stimulating factor (GMCSF), and
transforming growth factor-beta 3 indicate moderate benefits
for pain relief and mucosal healing, however these agents
are high-cost. Further research with expanded populations
and standardized assessment tools and study endpoints is
needed to identify the benefit of these agents.
A recent double-blind, placebo-controlled study of
palifermin (recombinant human keratinocyte growth factor),
which included 212 patients with hematologic cancers,
indicates a number of positive outcomes for mucositis pain
(Spielberger et al 2004). This growth factor mediates
epithelial cell growth and repair and may decrease apoptosis,
in addition to decreasing tumor necrosis factor-α. Patients
in the treatment arm of this study received palifermin 60
micrograms per kg per day IV for 3 days before and 3 days
after transplant. A decrease in incidence of Grade 3 and
Grade 4 mucositis (63% vs 98%; p<0.001), and a decreased
duration of mucositis (6 vs 9 days) were reported. A decrease
in patient-reported soreness of the mouth and throat was
also found, along with a decreased use of opioid analgesics
(212 mg vs 535 mg morphine equivalents). The use of total
parenteral nutrition (TPN) was also less in the treatment
group (Spielberger et al 2004).
Systemic analgesics
As described previously, mucositis is the most common side
effect which requires systemic analgesia during cancer
treatment. A survey of hospital pharmacists (n=62), three
institutions reported using intravenous opioids as initial
therapy and four indicated opioids as second-line therapy
(Mueller et al 1995). The current clinical practice guideline
provides a Level I, Grade A recommendation for patient-
controlled analgesia (PCA) with morphine for patient
undergoing hematopoietic stem cell transplant (HSCT).
Although the guideline does not endorse PCA morphine for
other patients with mucositis, it does include a
recommendation to follow current guidelines for managing
acute pain, such as the WHO analgesic ladder (Rubenstein
et al 2004).
Non-opioid strategies
Current literature on pain includes the use of a variety of
adjuvant treatments which can be used alone or in
conjunction with opioids to improve the efficacy of pain
management. Agents to consider include cyclo-
ogygenase-2 inhibitors, nonsteroidal antiinflammatory
drugs, and gabapentin (Epstein and Schubert 2004).
Cannabinoids, and alpha 2-adrenergic receptor agonists,
including clonidine, nicotine, lidocaine, and ketamine
may also be effective (Ripamonti and Dickerson 2001).
The effectiveness of these agents specifically for pain
relief needs further study.
Wong and Wilder-Smith (2002) evaluated the effects of
low level laser therapy (LLLT) on the incidence and severity
of chemotherapy-induced mucositis in patients (n=15) who
had developed Grade 3 or 4 mucositis during the previous
chemotherapy cycle. Using a laser device emitting at 803 nm,
all intra-oral tissues were irradiated to provide total energy
Table 4 Oral care protocol
Mouth care Recommended intake Avoid
· Floss once a day · Maintain appropriate fluid · Smoking
· Use a new, soft-bristled toothbrush once a month or with each chemo cycle intake (1–3 L/day) · Rough, hard foods
· Brush for 90 seconds 3 times daily · Maintain nutritional status Acidic foods
· Use fluoride toothpaste · Non-acidic fruits (grapefruit,  lemon
· Rinse w/ bland mouth rinse, 30 seconds, before meals and before bedtime. Do not swallow. (banana, mango, melon, orange)
peach) · Alcohol
· Keep lips lubricated · Alcohol-containing
and highly flavored
oral care products
Note: Sources are: Larson et al 1998; Epstein and Schubert 1999; Rubenstein et al 2004.Therapeutics and Clinical Risk Management 2006:2(3) 257
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densities of 0.8 J/cm
2. Laser treatment was preformed 24
hours before chemotherapy and once weekly until resolution
of mucositis or until the next chemotherapy treatment cycle.
In this study, 3 patients experienced Grade 1 to 2 mucositis,
and one patient experienced Grade 3 to 4 mucositis, which
interrupted treatment. While this modality shows positive
results in this small, study, more research is needed to
determine the effect of LLLT on pain and functionality as
well as prevention of mucositis.
Other novel therapies are gaining interest for treatment
and prevention of mucositis. Cryotherapy, or dissolving ice
chips in the patient’s mouth, has been recommended for
patients undergoing bolus fluorouracil administration
(Rubenstein et al 2004). Cryotherapy does not appear to be
of benefit for other patients or for pain management. L-
glutamine is an amino acid necessary for cell respiration in
rapidly dividing cells. In a double-blind placebo trial (n=24)
Anderson et al (1998) found that a 2 G/m
2 twice daily swish
and swallow formulation decreased the duration of mouth
pain and the number of days of restricted oral intake.
Preliminary phase III results indicate this agent may be
effective for prevention (Peterson et al 2004). This agent
also requires further study before treatment
recommendations can be made. Gelclair
® (OSI
Pharmaceuticals, Melville, NY, USA) is a bioadherent gel
consisting of sodium hyaluronate, polyvinylpyrrolidone, and
glycyrrhetinic acid (Peterson et al 2004). Although results
related to this agent are limited, it does appear to have a
role in pain relief and is US Food and Drug Administration
(FDA)-approved as a medical device.
Key recommendations
Mucositis is a common side effect with complex
pathophysiology, assessment, and treatment strategies.
Treatment is also confused by the use of “magic”
mouthwashes and lack of uniform oral protocols. As research
in this area continues to expand, systematic assessment
including visual assessment, pain, and patient function is
critical. Although publication of the first clinical practice
guideline for mucositis assists in clarifying prevention and
treatment methods, we must continue to provide patient-
appropriate interventions. Despite advances in research, no
one agent has shown to be more efficacious than following
current guidelines for acute pain management. Until novel
therapies are shown to be effective, multiple, evidenced-
based, interventional approaches are needed to decrease the
emotional and physical distress caused by acute oral pain
and mucositis. A mucositis-specific pain protocol should
be developed to address all elements of pain including tissue
damage, sensitization of pain receptors, and elaboration of
inflammatory and pain mediators. Clinicians must continue
to develop their understanding of the impact of the pain
and distress mucositis has for patients. Mucositis
management will improve through clinician and patient
education, appropriate assessment, and adequate
interventions.
Table 5 Growth factor mouthwashes
Reference Growth factor Type of study Sample Findings
Malik et al 1997 TCDO Double-blind, randomized, 62 patients with mucositis, Improved oral intake in
placebo-controlled  all diagnoses treatment group, shorter
subjective reports of pain
Karthaus et al 1998 G-CSF Random, placebo-controlled 8  patients over 32 chemo Significantly shorter hospital
cycles with high grade stays, fewer episodes of
lymphoma Grade 4 mucositis, earlier
recovery, reduction in need
for opioids in treatment
group
Bez et al 1999 GM-CSF Pilot study 10 patients with mucositis, Treatment group more likely
BMT to have symptoms lasting
<9 days
Foncuberta et al 2001 TGF-beta 3 Phase II double-blind, 125 patients with solid No effect
randomized, tumors or lymphomas
placebo-controlled
Melichar et al 2001 GM-CSF Pilot study 10 patients with Oral administration improves
chemotherapy-induced oral symptoms and
mucositis, 21 control normalizes intestinal
patients permeability
Abbreviatons: BMT, bone marrow transplant; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; TCDO,
chemically-stabilized chlorite-matrix; TGF, transforming growth factor.Therapeutics and Clinical Risk Management 2006:2(3) 258
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